Geode Capital Management LLC Acquires 74,194 Shares of Altimmune, Inc. (NASDAQ:ALT)

Geode Capital Management LLC raised its position in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 4.7% during the third quarter, according to its most recent filing with the SEC. The firm owned 1,668,004 shares of the company's stock after purchasing an additional 74,194 shares during the period. Geode Capital Management LLC owned 2.35% of Altimmune worth $10,244,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Bellevue Group AG grew its stake in Altimmune by 43.9% during the third quarter. Bellevue Group AG now owns 863,660 shares of the company's stock worth $5,303,000 after purchasing an additional 263,660 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Altimmune by 142.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company's stock worth $3,791,000 after buying an additional 335,444 shares during the period. BBR Partners LLC grew its position in shares of Altimmune by 4.5% during the 2nd quarter. BBR Partners LLC now owns 374,784 shares of the company's stock worth $2,492,000 after buying an additional 16,271 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Altimmune by 28.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 243,808 shares of the company's stock valued at $1,621,000 after acquiring an additional 54,154 shares in the last quarter. Finally, Exchange Traded Concepts LLC lifted its position in shares of Altimmune by 74.4% during the 3rd quarter. Exchange Traded Concepts LLC now owns 216,761 shares of the company's stock valued at $1,331,000 after acquiring an additional 92,498 shares during the period. 78.05% of the stock is owned by institutional investors.

Altimmune Trading Down 1.4 %

Shares of ALT traded down $0.10 on Thursday, reaching $7.11. The company's stock had a trading volume of 2,398,202 shares, compared to its average volume of 3,410,385. Altimmune, Inc. has a twelve month low of $5.28 and a twelve month high of $14.84. The stock has a market capitalization of $505.66 million, a PE ratio of -4.59 and a beta of 0.15. The firm has a fifty day moving average of $8.05 and a 200-day moving average of $7.16.

Altimmune (NASDAQ:ALT - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.03. The firm had revenue of $0.01 million during the quarter. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same period last year, the company earned ($0.39) earnings per share. As a group, equities analysts anticipate that Altimmune, Inc. will post -1.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ALT has been the subject of several research analyst reports. UBS Group assumed coverage on shares of Altimmune in a research note on Tuesday, November 12th. They issued a "buy" rating and a $26.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and issued a $12.00 target price on shares of Altimmune in a research report on Thursday, November 14th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $20.00.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.